about 3 min
Quick answer 30 sec
ADHD is a neurodevelopmental condition. It affects how you regulate attention, activity and impulses — especially when a task is boring, far away, or has no clear starting point. It isn’t a lack of intelligence or effort. It starts in childhood, often continues into adulthood, and looks different from one person to the next.
What this can feel like
Lived experience
You can focus for hours on something that grabs you, and not for four minutes on the email that actually matters.
People call you lazy. You know you’re working twice as hard just to look normal.
You lose the thread of what you were doing somewhere between the kitchen and the next room.
You’ve built a whole system of alarms, notes and last-minute panics to get through a week — and nobody sees it.
A composite of what people describe — not a checklist, not a test. ADHD, or just being human?
What’s happening 2–3 min
The name is misleading. ADHD is less a deficit of attention than a difficulty regulating it: pointing it where you want, keeping it there, and moving it when you need to. That’s why hyperfocus and distraction can live in the same person.
Officially there are two groups of symptoms: inattention (losing track, forgetting, avoiding tasks that need sustained mental effort) and hyperactivity–impulsivity (restlessness, interrupting, acting before thinking). In adults, hyperactivity often turns inward — a mind that never quite switches off.
For a diagnosis, symptoms must have started before age 12, show up in more than one area of life, and clearly get in the way. Everyone has some of these experiences. ADHD is about how many, how often, how long, and how much they cost.
ADHD is strongly influenced by genes — twin studies put heritability around 74% — but there’s no single ADHD gene. Thousands of small genetic variations each add a little, and environment matters too.
How sure are we?
Strong, replicated evidence — usually meta-analyses or international consensus. Unlikely to change much. What these labels mean ADHD is a valid, well-studied condition — not a label for ordinary distraction.
Faraone et al. 2021
- Consensus statement Faraone SV, Banaschewski T, Coghill D, et al. (80 authors) (2021). The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews, 128, 789–818. Open source ↗Only included findings from meta-analyses or studies with more than 2,000 participants.
Strong, replicated evidence — usually meta-analyses or international consensus. Unlikely to change much. What these labels mean About 2.6% of adults worldwide have ADHD that started in childhood and persisted; around 6.8% have adult symptoms above the diagnostic threshold.
Song et al. 2021
- Meta-analysis Song P, et al. (2021). The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. Journal of Global Health, 11, 04009. Open source ↗Persistent adult ADHD 2.58%; symptomatic adult ADHD 6.76%.
Strong, replicated evidence — usually meta-analyses or international consensus. Unlikely to change much. What these labels mean Genes account for roughly three-quarters of the differences between people, through many variants with small effects.
Faraone et al. 2019 +1
- Narrative review Faraone SV, Larsson H (2019). Genetics of attention deficit hyperactivity disorder. Molecular Psychiatry, 24, 562–575. Open source ↗Mean heritability ≈ 74% across twin studies.
- Cohort / register study Demontis D, Walters GB, Athanasiadis G, et al. (2023). Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nature Genetics, 55, 198–208. Open source ↗38,691 people with ADHD and 186,843 controls; mostly European ancestry.
Strong, replicated evidence — usually meta-analyses or international consensus. Unlikely to change much. What these labels mean Medication reduces core symptoms for many people in the short term.
Cortese et al. 2018 +1
- Meta-analysis Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. Open source ↗133 double-blind randomised trials; short-term outcomes (about 12 weeks).
- Meta-analysis Ostinelli EG, et al. (senior author: Cortese S) (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. Open source ↗Adults only. Short-term symptom benefits for stimulants and atomoxetine; little evidence on quality of life or long-term outcomes.
Strong, replicated evidence — usually meta-analyses or international consensus. Unlikely to change much. What these labels mean Executive-function difficulties are common but not universal: many people with ADHD score normally on lab tests (average group differences are moderate: working memory, inhibition, planning).
Willcutt et al. 2005 +1
- Meta-analysis Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF (2005). Validity of the executive function theory of ADHD: a meta-analytic review. Biological Psychiatry, 57(11), 1336–1346. Open source ↗83 studies. Moderate group differences; fewer than half of people with ADHD show impairment on any given executive task.
- Meta-analysis Pievsky MA, McGrath RE (2018). The neurocognitive profile of attention-deficit/hyperactivity disorder: a review of meta-analyses. Archives of Clinical Neuropsychology, 33(2), 143–157. Open source ↗34 meta-analyses; mean effect 0.45; working memory 0.54, response inhibition 0.52, planning/organisation 0.51.
What these labels mean
What else could explain this
Attention and focus problems have many possible causes. A careful assessment looks at these before (or alongside) ADHD:
- Anxiety or depression
- Poor or disrupted sleep, including sleep apnoea
- Trauma or long-term stress
- Thyroid problems and some other medical conditions
- Substance use, or some medications
- Other neurodevelopmental conditions such as autism or specific learning difficulties — which can also occur together with ADHD
The question isn’t “do I ever do this?” but “has this been persistent since childhood, across settings, and does it genuinely get in the way?”
Go deeper
Two ways in. Researchers disagree on a single core mechanism. Russell Barkley’s influential model puts behavioural inhibition at the centre: the ability to pause before responding, which the other executive functions depend on. Edmund Sonuga-Barke’s dual-pathway model adds a motivational route: a stronger aversion to waiting and delayed rewards. Joel Nigg and colleagues argue that different people may reach ADHD through different pathways.
Across the lifespan. ADHD symptoms often ease with age, but impairment frequently continues. Philip Asherson, Barbara Franke and colleagues describe adult ADHD as common, under-recognised and associated with real consequences for work, relationships and health.
The late-onset debate. Some long-term cohort studies found adults with ADHD symptoms who had no childhood diagnosis. Later work with repeated, detailed assessments found many of those cases were better explained by other conditions or substance use — while others likely had childhood symptoms that were masked or missed. This is still debated.
What we don’t know yet
- Why does ADHD look so different between people with the same diagnosis?
- How do genes and environment interact — and when in development does that matter most?
- What are the long-term effects of treatment, measured over decades rather than weeks?
- Can we predict who will benefit from which treatment?
Sources 15
- Consensus statement Faraone SV, Banaschewski T, Coghill D, et al. (80 authors) (2021). The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews, 128, 789–818. Open source ↗Only included findings from meta-analyses or studies with more than 2,000 participants.
- Meta-analysis Song P, et al. (2021). The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. Journal of Global Health, 11, 04009. Open source ↗Persistent adult ADHD 2.58%; symptomatic adult ADHD 6.76%.
- Narrative review Faraone SV, Larsson H (2019). Genetics of attention deficit hyperactivity disorder. Molecular Psychiatry, 24, 562–575. Open source ↗Mean heritability ≈ 74% across twin studies.
- Cohort / register study Demontis D, Walters GB, Athanasiadis G, et al. (2023). Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nature Genetics, 55, 198–208. Open source ↗38,691 people with ADHD and 186,843 controls; mostly European ancestry.
- Meta-analysis Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. Open source ↗133 double-blind randomised trials; short-term outcomes (about 12 weeks).
- Meta-analysis Ostinelli EG, et al. (senior author: Cortese S) (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. Open source ↗Adults only. Short-term symptom benefits for stimulants and atomoxetine; little evidence on quality of life or long-term outcomes.
- Meta-analysis Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF (2005). Validity of the executive function theory of ADHD: a meta-analytic review. Biological Psychiatry, 57(11), 1336–1346. Open source ↗83 studies. Moderate group differences; fewer than half of people with ADHD show impairment on any given executive task.
- Theory paper Barkley RA (1997). Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychological Bulletin, 121(1), 65–94. Open source ↗Source of the idea that help works best at the "point of performance".
- Theory paper Sonuga-Barke EJS (2003). The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neuroscience & Biobehavioral Reviews, 27(7), 593–604. Open source ↗Proposes an executive pathway and a motivational (delay aversion) pathway.
- Narrative review Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJS (2005). Causal heterogeneity in ADHD: do we need neuropsychologically impaired subtypes?. Biological Psychiatry, 57(11), 1224–1230. Open source ↗Different people with ADHD may get there through different routes.
- Narrative review Asherson P, Buitelaar J, Faraone SV, Rohde LA (2016). Adult attention-deficit hyperactivity disorder: key conceptual issues. The Lancet Psychiatry, 3(6), 568–578. Open source ↗
- Narrative review Franke B, Michelini G, Asherson P, et al. (2018). Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. European Neuropsychopharmacology, 28(10), 1059–1088. Open source ↗
- Cohort / register study Moffitt TE, Houts R, Asherson P, et al. (2015). Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. American Journal of Psychiatry, 172(10), 967–977. Open source ↗Dunedin cohort; most adult cases had no childhood diagnosis.
- Cohort / register study Sibley MH, Rohde LA, Swanson JM, et al. (2018). Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. American Journal of Psychiatry, 175(2), 140–149. Open source ↗Many apparent "late onset" cases were explained by other conditions or substance use.
- Clinical guideline American Psychiatric Association (2022). Diagnostic and Statistical Manual of Mental Disorders, 5th edition, text revision (DSM-5-TR). APA Publishing. Open source ↗Adults (17+): at least 5 symptoms in a domain; several before age 12; in 2+ settings; clear impairment.
Written: 2026-09 · Written from a structured literature review by a non-professional · Not yet reviewed by a clinician